BCR and cancer: The location and size of the bcr in de novo cancers appear to localize towards the centromeric end of the chromosome, but therapy-related cases tended to concentrate towards the telomeric 1kb region of this bcr, which are closer to topoisomerase-II cleavage sites, implicating these oncogenic DNA lesions as a direct consequence of topoisomerase action [73].